Tregs activated by bispecific antibodies: Killers or suppressors?

Koristka, Stefanie; Cartellieri, Marc; Arndt, Claudia; Feldmann, Anja; Seliger, Barbara; Ehninger, Gerhard; Bachmann, M. P.

doi:10.4161/2162402X.2014.994441

HZDR
Institutes
Research
Press & News
Career
Technology Transfer

Publications Repository - Helmholtz-Zentrum Dresden-Rossendorf

Total number to be selected: 1 Title record

1 Publication

Tregs activated by bispecific antibodies: Killers or suppressors?

Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Seliger, B.; Ehninger, G.; Bachmann, M. P.

In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or beneficial effects for tumor therapy is still controversially discussed.

Keywords: cytotoxicity; immunotherapy; immunsuppression; single-chain bispecific antibodies; T cell retargeting; T regulatory cells

OncoImmunology 4(2015)3, e994441
Online First (2015) DOI: 10.4161/2162402X.2014.994441
Cited 9 times in Scopus

Permalink: https://www.hzdr.de/publications/Publ-21715